Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Murat O. Arcasoy(Duke Medical Center), Roger M. Lyons(Hematology Oncology Associates), Ruben A. Mesa(The University of Texas MD Anderson Cancer Center), Richard T. Silver(NewYork–Presbyterian Hospital), Kris Vaddi(Incyte (United States)), John F. DiPersio(Washington University in St. Louis), Jason Gotlib(Stanford University), Vikas Gupta(Princess Margaret Cancer Centre), Azra Raza(Saint Vincent Health System), William Sun(Incyte (United States)), Elizabeth O. Hexner(University of Pennsylvania), Richard S. Levy(Incyte (United States)), Carole B. Miller(Fred Hutch Cancer Center), Jimmie H. Harvey, Ronald Paquette, E. Winton(Emory University), Susan Erickson‐Viitanen(Incyte (United States)), V. Sandor(Incyte (United States)), Michael W. Deininger(Oregon Health & Science University), John Catalano(Frankston Hospital), Moshe Talpaz(University of Michigan–Ann Arbor)
Cited by 162
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k